Skip to contentN
Neogenomics Inc
N
NEONeogenomics Inc Q2 2021 · 10-Q
Revenue$121.72M$121.72M+39.9% vs Q2 2020 Net Income$75.87M$75.87MN/M vs Q2 2020 EPS Diluted$0.59$0.59N/M vs Q2 2020 Gross Profit$52,990,000+89.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Neogenomics Inc · CIK 1077183 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,390,000N/M Free Cash Flowderived-$22,737,000N/M Margins · derivedGross margin43.5%+11.3 pt vs Q2 2020
Operating margin-18.4%+3.4 pt vs Q2 2020
Net margin62.3%+70.2 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 9, 2021 · 40 d after period end